/

IRD

Opus Genetics, Inc.Open

4.13−0.11 −2.71%USD

NasdaqCM · as of Oct 14, 15:38 ET · 15m delay

Open

4.24

Prev close

4.24

Day range

4.084.37

52-week range

1.707.07

Volume

861.75K0.36×

Mkt cap

343.18M

P/E ttm

—

Fwd P/E

-5.77

EPS ttm

-1.27

Div yield

0.00%

Earnings

Aug 6, 2026

From 52w high

−41.65%

Price Chart

Yahoo Finance · delayed

IRDOct 14, 2026O 4.24H 4.37L 4.08C 4.13−0.11 (−2.71%)Vol 861.75K

SMA 504.48
SMA 2004.08

1Y change +106.25% since Oct 13, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

IRD Opus Genetics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −6.46%
1 month: −30.90%
3 months: +18.53%
6 months: −27.76%
Year to date: +105.22%
1 year: +106.25%

Valuation & ownership

Market cap: 343.18M
Enterprise value: 300.14M
P/E (ttm): —
Forward P/E: -5.77
PEG ratio: —
Price / book: —
Price / sales (ttm): 34.82
EV / EBITDA: -5.94
EPS (ttm): -1.27
EPS (forward): -0.7150
Beta (5y monthly): 0.62
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 83.20M
Float: 64.68M
Short % of float: 16.45%
Short ratio (days): 2.62
Held by insiders: 12.23%
Held by institutions: 69.27%
Avg volume (3m): 2.40M
50-day average: 4.47
200-day average: 4.07
52-week change: +106.25%
S&P 500 52-week: +17.00%

Technicals (daily)

RSI (14): 38.3
vs 50-day SMA: −7.89%
vs 200-day SMA: +1.06%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 9.28%
Realised vol (20d, ann.): 57.4%
From 52-week high: −41.65%
From 52-week low: +142.65%

ANR

Analyst Consensus

17 analysts

Consensus

Strong buy

1.17 on a 1 (strong buy) – 5 (sell) scale

Mean target

13.41

+225.13% implied

Low 8.00Median 13.00High 20.00

Recommendation trend

Now18 / 0 / 0
1m ago18 / 0 / 0

DES

About Opus Genetics, Inc.

Yahoo Finance profile

Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene. In addition, it develops Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as for the treatment of presbyopia and dim light or night vision disturbances and APX3330, a small-molecule inhibitor of Ref-1 for the treatment of diabetic retinopathy. Opus Genetics, Inc. was formerly known as Ocuphire Pharma, Inc. and changed its name to Opus Genetics, Inc. in November 2020. The company was founded in 2018 and is headquartered in Durham, North Carolina.

Sector: Healthcare
Industry: Biotechnology
Employees: 27
Headquarters: Durham, NC, United States
Website: opusgtx.com
Officers

SEAS

Seasonality · IRD

2007–2026 · monthly returns

Strongest month Jan +12.62%Weakest month Oct −8.81%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	14.9	80.1	9.4	12.3	-14.7	-5.7	-9.7	-2.4	33.7	-14.8			+105.2%
2025	-6.7	-7.2	-4.9	-3.1	4.2	-5.1	18.1	9.9	35.2	39.4	-7.4	-5.6	+68.9%
2024	-13.0	-3.1	-20.9	-20.9	5.7	-8.9	30.1	-37.7	5.6	-8.4	-7.5	7.2	−60.5%
2023	-1.7	-0.6	8.7	36.8	-24.8	12.4	-0.2	-7.9	-16.0	-14.9	7.0	-1.3	−14.7%
2022	-15.0	7.9	-5.3	-27.8	-9.4	-9.4	-2.6	21.4	-11.5	16.9	31.1	14.6	−5.4%
2021	79.8	-9.1	-45.2	-12.4	-10.8	16.3	-20.5	6.0	15.7	-23.5	-0.8	-4.6	−42.5%
2020	7.3	13.7	-22.7	5.6	32.1	13.1	-6.3	-14.3	-8.8	3.4	-28.4	5.4	−15.1%
2019	-31.2	-18.8	-1.9	-2.8	-17.1	4.7	-0.8	-57.2	-6.4	-18.0	3.0	10.4	−82.9%
2018	3.5	-23.4	-5.6	15.2	28.7	-37.1	7.1	13.9	3.5	-35.4	-6.1	-13.9	−54.0%
2017	21.4	47.1	104.0	-15.7	-11.6	-24.7	-26.2	14.2	0.4	-27.3	22.2	-6.0	+44.3%
2016	0.0	-2.8	-5.7	-9.1	6.7	-21.9	4.0	-3.8	-16.0	-19.0	0.0	-17.6	−61.1%
2015	4.3	9.6	-8.8	-1.4	1.4	-16.4	-11.5	5.6	-8.8	-15.4	2.3	-20.0	−48.6%
2014	125.5	17.4	-20.0	-12.0	-3.2	-5.4	-13.8	-6.7	15.7	-11.1	-6.9	4.5	+37.3%
2013	3.2	-3.1	0.0	3.2	6.2	29.4	18.2	-26.9	18.4	-8.9	-2.4	27.5	+64.5%
2012	68.4	-18.8	1.9	-18.9	-4.7	-22.0	53.1	-4.1	8.5	-19.6	-19.5	-6.1	−18.4%
2011	31.3	8.2	-25.8	2.5	8.3	-5.3	-3.2	-20.8	5.3	3.0	-54.4	-19.1	−66.1%
2010	-2.9	89.4	29.6	22.8	-27.6	-0.7	-3.5	-15.2	-0.9	-4.3	-8.1	9.8	+64.7%
2009	-27.0	-7.7	16.7	-7.1	75.4	-27.2	-6.0	19.2	-5.4	-27.3	1.6	4.6	−23.6%
2008	-6.7	4.3	14.2	-6.0	71.9	-19.8	-56.5	-29.1	29.0	-14.7	-17.3	-2.2	−60.4%
2007	-0.7	0.7	29.6	37.1	-41.7	36.4	-18.8	-7.7	-2.1	17.9	-9.1	50.0	+66.7%

IRD

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

IRD

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Opus Genetics, Inc.

Seasonality · IRD

Insider Activity · IRD

Congress Trades · IRD

Investors Holding IRD

Investors Holding IRD

Congress Trades · IRD

Insider Activity · IRD

Seasonality · IRD

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Opus Genetics, Inc.

Financial Snapshot

Earnings & Dividends

News